Eurofins-Cerep SA (FR:ALECR) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eurofins-Cerep SA reported a decrease in revenue for the first semester of 2024, down by 7.68% from the previous year, amid a contracting drug discovery market. Despite this, the company saw a positive financial result from cash investments and exchange rates, as well as progress in R&D with new pharmacological test applications and a biophysics platform for drug research. Looking ahead, the firm anticipates that renewed and developing contracts will mitigate turnover declines in the latter half of 2024.
For further insights into FR:ALECR stock, check out TipRanks’ Stock Analysis page.